Compare MMT & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMT | PYXS |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.0M | 243.5M |
| IPO Year | N/A | 2021 |
| Metric | MMT | PYXS |
|---|---|---|
| Price | $4.72 | $4.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 86.5K | ★ 683.6K |
| Earning Date | 01-01-0001 | 11-03-2025 |
| Dividend Yield | ★ 8.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | N/A | ★ $2,820,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.33 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.04 | $0.83 |
| 52 Week High | $4.70 | $5.55 |
| Indicator | MMT | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 52.86 | 49.89 |
| Support Level | $4.67 | $4.11 |
| Resistance Level | $4.75 | $4.35 |
| Average True Range (ATR) | 0.04 | 0.42 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 72.41 | 32.98 |
MFS Multimarket Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests a majority of its net assets in fixed-income securities, corporate bonds of the U.S and foreign issuers, U.S Government securities, foreign government securities, mortgage-backed and other asset-backed securities of U.S and foreign issuers, and debt instruments of issuers located in emerging market countries. The portfolio of investments comprises of different sector investments such as aerospace, airlines, automotive, chemicals, electronics, and others.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.